cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
A patient death notwithstanding, Chi-Med reckons results from the Tatton study justify its US registration strategy.
Experimental therapeutics from Bridgebio, Incyte and Johnson & Johnson, all targeting FGFR, show promise in patients whose tumours are driven by this genetic…
Chi-Med is not alone in seeing Chinese approval as the prelude to a regulatory green light in the west.
Novartis hails the most advanced alpha-directed PI3K inhibitor after success in breast cancer, but it’s not the only one.